Makoto Nishio
- Oncology top 0.1%
- Lung Cancer Research Studies 168
- Colorectal Cancer Treatments and Studies 92
- Cancer Immunotherapy and Biomarkers 75
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations 313
- Lung Cancer Diagnosis and Treatment 102
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 51
- Molecular Biology top 2%
- Cancer therapeutics and mechanisms 52
- Epidemiology top 2%
- Neuroendocrine Tumor Research Advances 31
Makoto Nishio
423 papers receiving 11.6k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Oncology 8.5k
- Pulmonary and Respiratory Medicine 8.1k
- Cancer Research 1.8k
- Molecular Biology 2.9k
- Epidemiology 1.3k
Countries citing papers authored by Makoto Nishio
This map shows the geographic impact of Makoto Nishio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Makoto Nishio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Makoto Nishio more than expected).
Fields of papers citing papers by Makoto Nishio
This network shows the impact of papers produced by Makoto Nishio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Makoto Nishio. The network helps show where Makoto Nishio may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Makoto Nishio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 4 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 5 | |
| 8 | 2024 | 1 | |
| 9 | 2023 | 4 | |
| 10 | 2023 | 7 | |
| 11 | 2022 | 8 | |
| 12 | 2021 | 29 | |
| 13 | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)breakdown → | 2021 | 484 |
| 14 | 2021 | 37 | |
| 15 | 2021 | 16 | |
| 16 | 2020 | 14 | |
| 17 | 2019 | 10 | |
| 18 | 2019 | 79 | |
| 19 | 2019 | 5 | |
| 20 | 2018 | 23 |
About Makoto Nishio
Makoto Nishio is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 444 papers that have together received 11.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (313 papers), Lung Cancer Research Studies (168 papers), Lung Cancer Diagnosis and Treatment (102 papers), Colorectal Cancer Treatments and Studies (92 papers), Cancer Immunotherapy and Biomarkers (75 papers), Cancer therapeutics and mechanisms (52 papers), Cancer Genomics and Diagnostics (51 papers) and Neuroendocrine Tumor Research Advances (31 papers). The work is most often cited by research in Oncology (8.5k citations), Pulmonary and Respiratory Medicine (8.1k citations) and Cancer Research (1.8k citations). Makoto Nishio has collaborated with scholars based in Japan, United States and Spain. Frequent co-authors include Takashi Seto, Toyoaki Hida, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Tony Mok, Kōichi Goto, Tomohide Tamura, Naoyuki Nogami, Yuichiro Ohe and Atsushi Horiike. Their work appears in journals such as Nature Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.